Angiotensin-(1-7) Reduces Fibrosis in Orthotopic Breast Tumors

被引:79
作者
Cook, Katherine L. [1 ,2 ]
Metheny-Barlow, Linda J. [3 ]
Tallant, E. Ann [1 ,2 ]
Gallagher, Patricia E. [1 ]
机构
[1] Wake Forest Univ, Bowman Gray Sch Med, Hypertens & Vasc Res Ctr, Winston Salem, NC 27157 USA
[2] Wake Forest Univ, Bowman Gray Sch Med, Mol Med & Translat Sci Program, Winston Salem, NC 27157 USA
[3] Wake Forest Univ, Bowman Gray Sch Med, Dept Radiat Oncol, Winston Salem, NC 27157 USA
关键词
GROWTH-FACTOR; CANCER XENOGRAFTS; CARDIAC FIBROSIS; RECEPTOR MAS; CELL-GROWTH; PROGNOSTIC VALUE; INHIBITS GROWTH; NUDE-MICE; FIBROBLASTS; THERAPY;
D O I
10.1158/0008-5472.CAN-10-1136
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Angiotensin-(1-7) [Ang-(1-7)] is an endogenous 7-amino acid peptide hormone of the renin-angiotensin system that has antiproliferative properties. In this study, Ang-(1-7) inhibited the growth of cancer-associated fibroblasts (CAF) and reduced fibrosis in the tumor microenvironment. A marked decrease in tumor volume and weight was observed in orthotopic human breast tumors positive for the estrogen receptor (BT-474 or ZR-75-1) and HER2 (BT-474) following Ang-(1-7) administration to athymic mice. Ang-(1-7) concomitantly reduced interstitial fibrosis in association with a significant decrease in collagen I deposition, along with a similar reduction in perivascular fibrosis. In CAFs isolated from orthotopic breast tumors, the heptapeptide markedly attenuated in vitro growth as well as reduced fibronectin, transforming growth factor-beta (TGF-beta), and extracellular signal-regulated kinase 1/2 kinase activity. An associated increase in the mitogen-activated protein kinase (MAPK) phosphatase DUSP1 following treatment with Ang-(1-7) suggested a potential mechanism by which the heptapeptide reduced MAPK signaling. Consistent with these in vitro observations, immunohistochemical analysis of Ang-(1-7)-treated orthotopic breast tumors revealed reduced TGF-beta and increased DUSP1. Together, our findings indicate that Ang-(1-7) targets the tumor microenvironment to inhibit CAF growth and tumor fibrosis. Cancer Res; 70(21); 8319-28. (C) 2010 AACR.
引用
收藏
页码:8319 / 8328
页数:10
相关论文
共 50 条
[1]
Targeting the Tumor Stroma in Cancer Therapy [J].
Anton, Kevin ;
Glod, John .
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2009, 10 (02) :185-191
[2]
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy [J].
Arpino, Grazia ;
Gutierrez, Carolina ;
Weiss, Heidi ;
Rimawi, Mothaffar ;
Massarweh, Suleiman ;
Bharwani, Lavina ;
De Placido, Sabino ;
Osborne, C. Kent ;
Schiff, Rachel .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (09) :694-705
[3]
Mitogen-activated protein (MAP) Kinase/MAP kinase phosphatase regulation: Roles in cell growth, death, and cancer [J].
Boutros, Tarek ;
Chevet, Eric ;
Metrakos, Peter .
PHARMACOLOGICAL REVIEWS, 2008, 60 (03) :261-310
[4]
Cardone A, 1997, PANMINERVA MED, V39, P174
[5]
Couillard S, 1998, CANCER RES, V58, P60
[6]
Stromal myofibroblasts are drivers of invasive cancer growth [J].
De Wever, Olivier ;
Demetter, Pieter ;
Mareel, Marc ;
Bracke, Marc .
INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (10) :2229-2238
[7]
REPRESSION OF THE TRANSFORMING GROWTH-FACTOR-BETA-1 GENE BY THE WILMS-TUMOR SUPPRESSOR WT1 GENE-PRODUCT [J].
DEY, BR ;
SUKHATME, VP ;
ROBERTS, AB ;
SPORN, MB ;
RAUSCHER, FJ ;
KIM, SJ .
MOLECULAR ENDOCRINOLOGY, 1994, 8 (05) :595-602
[8]
Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas:: development of a novel mouse lung tumor model [J].
Floyd, HS ;
Farnsworth, CL ;
Kock, ND ;
Mizesko, MC ;
Little, JL ;
Dance, ST ;
Everitt, J ;
Tichelaar, J ;
Whitsett, JA ;
Miller, MS .
CARCINOGENESIS, 2005, 26 (12) :2196-2206
[9]
Angiotensin-(1-7) inhibits vascular smooth muscle cell growth [J].
Freeman, EJ ;
Chisolm, GM ;
Ferrario, CM ;
Tallant, EA .
HYPERTENSION, 1996, 28 (01) :104-108
[10]
Inhibition of human lung cancer cell growth by angiotensin-(1-7) [J].
Gallagher, PE ;
Tallant, EA .
CARCINOGENESIS, 2004, 25 (11) :2045-2052